Invention Grant
- Patent Title: Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor I
-
Application No.: US16212455Application Date: 2018-12-06
-
Publication No.: US11124501B2Publication Date: 2021-09-21
- Inventor: Keith Jones , Carl Rye , Nicola Chessum , Matthew Cheeseman , Adele E. Pasqua , Kurt G. Pike , Paul F. Faulder
- Applicant: Cancer Research Technology Limited
- Applicant Address: GB London
- Assignee: Cancer Research Technology Limited
- Current Assignee: Cancer Research Technology Limited
- Current Assignee Address: GB London
- Agency: Goodwin Procter LLP
- Priority: GB1317609 20131004
- Main IPC: C07D405/12
- IPC: C07D405/12 ; C07D405/14 ; C07D319/18 ; C07D407/12 ; C07D409/12 ; C07D417/12 ; C07D417/14 ; C07D471/04 ; C07D487/08 ; C07D491/056 ; A61K31/357 ; A61K31/404 ; A61K31/428 ; A61K31/436 ; A61P35/00
Abstract:
The present invention relates to compounds of formula I as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 (HSF1). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
Public/Granted literature
- US20190106413A1 INHIBITOR COMPOUNDS Public/Granted day:2019-04-11
Information query
